Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models

BACKGROUND: Sym004 is a mixture of two monoclonal antibodies (mAbs), futuximab and modotuximab, targeting non-overlapping epitopes on the epidermal growth factor receptor (EGFR). Previous studies have shown that Sym004 is more efficient at inducing internalization and degradation of EGFR than indivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Keir, Stephen T., Chandramohan, Vidyalakshmi, Hemphill, Carlee D., Grandal, Michael M., Melander, Maria Carlsen, Pedersen, Mikkel W., Horak, Ivan D., Kragh, Michael, Desjardins, Annick, Friedman, Henry S., Bigner, Darell D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Laboratory Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999169/
https://www.ncbi.nlm.nih.gov/pubmed/29564747
http://dx.doi.org/10.1007/s11060-018-2832-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999169/
https://www.ncbi.nlm.nih.gov/pubmed/29564747
http://dx.doi.org/10.1007/s11060-018-2832-6

Ejemplares similares